Main Content

Recall Alerts

Recall Alerts

Zantac OTC (over-the-counter)

Zantac OTC (over-the-counter)

Zantac OTC (over-the-counter)

October 18, 2019

Sanofi to conduct precautionary voluntary recall of Zantac OTC in U.S. and Canada BRIDGEWATER, NJ – October 18, 2019 – As a precautionary measure, Sanofi will conduct a voluntary recall of Zantac OTC (over-the-counter) in the U.S. and Canada. This recall is being taken due to possible contamination with a nitrosamine impurity called Nnitrosodimethylamine (NDMA). The company is working with health authorities to determine the level and extent of the recall. On September 13, 2019, the U.S Food and Drug Administration and Health Canada issued public statements alerting that some ranitidine medicines, including Zantac OTC, could contain NDMA at low levels and asked manufacturers to conduct testing. Evaluations are ongoing on both drug substance (active ingredient) and finished drug product. Due to inconsistencies in preliminary test results of the active ingredient used in the U.S. and Canadian products, Sanofi has made the decision to conduct the voluntary recall in the U.S. and Canada as the investigation continues. Active ingredients used in Sanofi’s ranitidine products outside of the U.S. and Canada are sourced from different suppliers. Sanofi is committed to transparency and will continue to communicate results with health authorities from the ongoing testing, and work with them to make informed decisions based on available data and evidence. Sanofi encourages anyone using Zantac OTC to speak with their health care providers or pharmacists if they have any additional questions.

About Sanofi: Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe. Sanofi, Empowering Life

For Our Consumers

Media Relations Contact 

Ashleigh Koss

Tel.: 908-981-8745Ashleigh.Koss@sanofi.com

Investor Relations Contact

George Grofik

Tel.: +33 (0)1 53 77 45 45ir@sanofi.com

We apologize for any inconvenience this situation may have caused.